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Abstract
Background: Many reports shoed that for patients with acute coronary syndrome (ACS) 
increased admission blood glucose (ABG) level is associated with adverse outcomes. Although 
scientific reports on this issue are still inconsistent, many recent studies confirm that hyper-
glycemia is also an unfavorable prognostic factor in patients with ACS complicated by cardio-
genic shock (CS). The aim of this study is to determine if hyperglycemia on admission can be  
a predictor of in-hospital death in patients with ACS complicated by CS.
Methods: The study population consisted of 40 patients with ACS complicated by CS admit-
ted to the Intensive Cardiac Therapy Clinic from January 2010 to May 2013 and treated with 
primary percutaneous coronary intervention. A control group was selected among patients with 
uncomplicated ACS.
Results: Patients with CS had significantly higher levels of ABG (15.4 ± 6.26 vs. 7.97 ±  
± 2.28 mmol/L, p < 0.01) in comparison with the control group. There was no statistically 
significant correlation between the level of glucose on admission and in-hospital mortality. 
Average ABG in patients who survived and in those who died were respectively 15.42 ± 5.61 
vs. 15.40 ± 6.87 mmol/L, p > 0.05. Comparison in groups depending on ABG level and cal-
culations with use of receiver-operating characteristics curves showed no relationship between 
the level of ABG and patients’ deaths.
Conclusions: Hyperglycemia on admission is a clinical feature of patients with ACS who de-
velop CS, however its prognostic value requires further studies. (Cardiol J 2015; 22, 3: 290–295)
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Introduction
The most serious disease of the cardiovascu-
lar system is acute myocardial infarction (AMI). 
Although numerous clinical complications are 
associated with AMI, none are more potentially 
devastating or carry a worse prognosis than car-
diogenic shock (CS) [1]. It occurs in 5% to 8% of 
patients hospitalized with AMI. This translates into 
approximately 40,000–50,000 cases per year in the 
United States and approximately 60,000–70,000 
cases in Europe [2]. Despite advances in treatment 
during the last two decades, CS still remains the 
major cause of death with hospital mortality rates 
approaching 50% [2–5]. Appropriate monitoring, 
risk stratification and intervention from first medi-
cal contact can be undertaken after the onset of 
AMI symptoms only when we focus on identify-
ing patients who are at high risk of CS develop-
ment. Therefore, looking for simple, easily and 
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fast measurable prognostic factors of this deadly 
complication risk could be the next milestone in 
saving patients with myocardial infarction.
Hyperglycemia is an independent predictor 
of death in many acute states like trauma, head 
injury, stroke or acute coronary syndrome (ACS). 
It causes harm to critically ill through a variety 
of mechanisms including concurrent activation of 
inflammatory process and producing a hyperco-
agulable state [6].
It has been shown that for patients with AMI, 
increased admission blood glucose (ABG) level has 
been associated with adverse outcomes including 
death [7]. The prevalence of admission hypergly-
cemia (glucose levels ≥ 7.8 mmol/L) in different 
epidemiological studies ranges from 51% to > 58% 
of patients hospitalized with AMI [8]. Increased 
glucose level on admission is an independent factor 
of more impaired initial flow in the infarct-related 
artery and occurrence of no-reflow phenomenon 
[9]. In addition, patients with hyperglycemia have 
higher Killip class, a larger infarct and worse 
left ventricular (LV) function [10]. Also higher 
incidence of CS has been observed among hyper-
glycemic patients with AMI [11, 12]. Although, 
scientific reports on this issue are still inconsistent, 
many recent studies confirm that hyperglycemia is 
an unfavorable prognostic factor in AMI patients 
complicated by CS [11, 13–15].
Since measurement of blood glucose (BG) 
level is simple and fast, it is highly important 
whether hyperglycemia on admission can be an 
independent predictor of death in patients with CS.
The aim of this study is to determine if hypergly-
cemia on admission can be a predictor of in-hospital 
death in patients with ACS complicated by CS.
Methods
Study population
The population of our prospective study con-
sisted of 40 patients with ACS complicated with CS 
(CS [+] group), admitted to the Intensive Cardiac 
Therapy Clinic during the period from January 2010 
to May 2013 and treated with primary percutane-
ous coronary intervention (PCI). A control group 
(CS [–] group) was selected among age- , gender- and 
infarct location-matched patients with uncompli-
cated ACS. All patients enrolled in the study were 
transported to the hospital by ambulance directly 
from home or another location of the event. The 
main criteria for exclusion from the study were: 
shock from non-cardiac causes, transfer from other 
hospitals, prehospital cardiac arrest.
Study protocol
We used the contemporary definition of AMI 
to confirm the diagnosis of ST elevation myocar-
dial infarction (STEMI): typical clinical symptoms, 
persistent ST segment elevation ≥ 0.2 mV in two 
of V2–V3 leads or  ≥ 0.1 mV in two of other con-
tiguous leads or new left bundle branch block in 
electrocardiography (ECG) and elevation of myo-
cardial necrosis markers (troponin T, creatinine 
kinase-MB fraction) [16]. The diagnosis of non-
STEMI (NSTEMI) was made on the basis of typical 
chest pain and elevated biochemical markers of 
myocardial necrosis after exclusion of elevation of 
ST-segment in ECG [17]. CS diagnosis was based 
on clinical findings (cold, clammy skin, oliguria 
or anuria) and hemodynamic criteria including 
systemic systolic blood pressure < 90 mm Hg or 
decrease by 30 mm Hg compared to baseline last-
ing for at least 30 min without the use of inotropic 
support or intraaortic balloon pump. Patients with 
CS as a result of mechanical complications of AMI 
(acute mitral valve regurgitation, ventricular septal 
rupture) and other causes of hypotension such as 
arrhythmias, hypovolemia, vasovagal reactions, 
electrolyte disturbances, pharmacological side-
effects or cardiac tamponade were excluded from 
the study.
We assembled baseline characteristics such 
as demographic data, cardiovascular history, risk 
factors (diabetes mellitus, smoking status, hyper-
tension), prior embolic events and family history 
of cardiac artery disease (Table 1). We classified 
all patients who had been treated with insulin, oral 
antihyperglycemic agents or lifestyle modification 
and had previous history of diabetes mellitus (DM) 
patients.
ABG level samples were collected in the emer-
gency room for all patients and measured with an 
arterial blood gas analyzer or laboratory analyzers 
routinely used at each hospital. For purposes of 
this study and adhering to the recommendations 
of the Polish Diabetes Association [18], patients 
were divided into three groups depending of ABG: 
normoglycemic (≤ 7.8 mmol/L), impaired glucose 
tolerance (IGT) group (7.8–11.1 mmol/L) and acute 
hyperglycemia group (> 11.1 mmol/L). All patients 
with previously diagnosed DM and those with hy-
perglycemia received antihyperglycemic therapy.
All patients were treated with primary PCI of 
the infarct-related artery which was identified on 
the basis of ECG and coronary angiography find-
ings. PCI was performed using standard equipment 
and techniques including stent implantation. The 
angiographic success of revascularization was 
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defined as the Thrombolysis In Myocardial Infarction 
(TIMI) 3 flow.
The study was approved by the local research 
Ethics Committee.
Statistical analysis
Statistical analysis of the data was carried out 
using Statistica 10.0 set. Continuous variables 
were presented as means ± standard deviation. 
Comparisons between groups were performed 
using the c2 test, non-parametric Mann-Whitney 
test, Kruskal-Wallis test for continuous variables. 
Statistical significance was assumed at a p value 
of < 0.05.
Results
Forty patients were included in the study. 
The control group was collected from age-, gen-
der- and infarct location-matched patients with 
uncomplicated ACS. The mean age in both groups 
was almost the same 71.5 ± 11.1 vs. 71.6 ± 11.1, 
respectively. Exactly half of patients were male in 
the groups. There were no statistically significant 
differences in risk factors between patients with 
or without CS (Table 1). Only previous stroke was 
presented more often in CS [+] group (respectively 
15% vs. 3%, p < 0.05). STEMI patients were in 
the majority in both groups (90% vs. 88%). None 
of uncomplicated ACS patients died when mortality 
rate in CS [+] group reached 22 (55%) patients.
In comparison with the control group, pa-
tients who developed CS during hospitalization 
had significantly higher BG levels on admission, 
respectively 15.4 ± 6.26 vs. 7.97 ± 2.28 mmol/L, 
p < 0.01 (Fig. 1). This difference was strongly 
expressed in both DM and non-DM. Average ABG 
level in patients without DM history in CS [+] and 
CS [–] group was, respectively, 14.8 ± 6.03 vs. 
8.00 ± 2.35 mmol/L (p < 0.001). Statistically signi-
Table 1. Baseline characteristics of patients with [CS (+)] and without [CS (–)] cardiogenic shock.
Parameters CS (+), n = 40 CS (–), n = 40 P 
Male 20 (50%) 20 (50%)
Female 20 (50%) 20 (50%)
ST elevaion MI 36 (90%) 35 (88%)
Non-ST elevation MI 4 (10%) 5 (12%)
Fatal outcome 22 (55%) 0 (0%) < 0.001
CAD history 21 (53%) 22 (55%) > 0.05
Prior MI 10 (25%) 11 (28%) > 0.05
Prior PCI/CABG 6 (15%) 9 (23%) > 0.05
Previous stroke 6 (15%) 1 (3%) < 0.05
Family history of CAD 6 (15%) 3 (8%) > 0.05
Hypertension 18 (45%) 24 (60%) > 0.05
Diabetes 7 (18%) 4 (10%) > 0.05
Smokers 9 (23%) 8 (20%) > 0.05
CABG — coronary artery bypass graft; CAD — coronary artery disease; MI — myocardial infarction; PCI — percutaneous coronary intervention
Figure 1. Admission blood glucose (ABG) levels in pa-
tients from the study and the control group, CS (+) — 
patients with cardiogenic shock, study group; CS (–) — 
patients without cardiogenic shock, control group; 
DM (+) — patients with prior diagnosis of diabetes melli- 
tus; DM (–) — patients without prior diagnosis of dia-
betes mellitus.
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ficant difference in BG level between the study and 
control group are also present in diabetics, respec-
tively 18.1 ± 7.09 vs. 7.73 ± 1.72 mmol/L (p < 0.05). 
In the study group, a huge majority of patients — 
31 (78%) were those with acute hyperglycemia (ABG 
> 11.1 mmol/L). The opposite trend was observed 
in the control group where 21 (53%) patients were 
normoglycemic (ABG < 7.8 mmol/L), 17 (42%) 
patients had IGT (ABG 7.8–11.1 mmol/L) and only 
2 (5%) patients were hyperglycemic (Table 2). The 
difference was statistically significant — p < 0.001.
Evaluation of the relationship between the 
level of BG on admission and sex in CS [+] group 
showed that distribution of hyperglycemia in 
a group of men and women was almost the same. 
In both sexes, the vast majority of respondents 
characterized the glucose level > 11.1 mmol/L 
(respectively 15 [75%] men and 16 [80%] women). 
Only 1 in 10 women and 1 in 10 men had a BG con-
centration of 7.8–11.1 mmol/L. Similarly, 15% of 
women and 10% of men were normoglycemic (ABG 
< 7.8 mmol/L). Due to the reports of other re-
search [19], we evaluated the relationship between 
sex and death in patients with acute hyperglycemia 
(ABG > 11.1 mmol/L). In this study, gender did not 
affect mortality rates in patients with the highest 
levels of ABG — respectively 9 (60%) women vs. 
7 (44%) men died (p > 0.05).
Also the presence of chest pain was not related 
to glucose levels on admission in CS [+] group. 
Mean ABG level in patients with or without steno-
cardia was, respectively, 17.4 ± 8.20 vs. 15.0 ± 
± 5.84 mmol/L (p = NS). Although the CS [–] group 
demonstrated a statistically significant relationship 
between the level of BG and the presence of chest 
pain, the pain-free patients presented higher levels 
of ABG, respectively 7.61 ± 1.69 vs. 12.5 ± 
± 4.07 mmol/L (p < 0.051).
There was no statistically significant correla-
tion between the level of glucose on admission 
and in-hospital mortality (Fig. 2). Average ABG in 
patients who survived and in those who died were, 
respectively, 15.42 ± 5.61 vs. 15.40 ± 6.87 mmol/L 
(p > 0.05). Comparison in groups depending on 
ABG level, did not confirm that hyperglycemia is 
a predictor of death in ACS complicated by CS.
Discussion
Despite the continuous improvement of proce-
dures for the treatment from first medical contact, 
early revascularization techniques and intensive 
care, the mortality rate in patients with ACS com-
plicated by CS has not reduced for many years. This 
study tried to answer if hyperglycemia diagnosed 
on admission is associated with increased risk of 
in-hospital death in CS patients.
Our study confirmed the presence of hyper-
glycemia in almost all patients with CS. We clearly 
showed that regardless of DM status and sex, 
hyperglycemia was a part of the clinical characteris-
tics of patients with ACS complicated by CS. What 
is more, levels of ABG were significantly higher in 
patients with CS than in those who did not develop 
this deadly complication.
Mechanisms for this hyperglycemia in pa-
tients with CS remain not fully explained. Some 
research connect high BG levels with the degree of 
biological stress which leads to secretion of stress 
hormones, including catecholamines, cortisol, 
various inflammatory cytokines and a promotion of 
Figure 2. Correlation between admission blood glucose 
level and fatal outcome in patients with cardiogenic shock; 
CI — confidence interval; AUC — area under the curve.
Table 2. The division into groups depending  
on the level of admission blood glucose (ABG)  




CS (+),  
n = 40
CS (–),  
n = 40
P 
< 7.8 5 (12%) 21 (53%) < 0.001
7.8–11.1 4 (10%) 17 (42%) < 0.001
> 11.1 31 (78%) 2 (5%) < 0.001
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glycogenolysis and gluconeogenesis [20]. Insulin 
resistance is also inducted by growth hormone and 
free fatty acids [6]. Stress hyperglycemia has been 
reported to promote platelet activation which is 
responsible for impaired microcirculation and cell 
damage exacerbation [21].
The phenomenon of hyperglycemia in serious, 
acute illnesses has been more widely studied in re-
cent years. Braeley et al. [6] showed that increased 
BG level causes harm through a variety of ways 
in critically ill. Recent study of Mansour et al. [7] 
confirmed that increased BG level (≥ 7.8 mmol/L) 
is an unfavorable prognostic factor also in patients 
with ACS. Hyperglycemia in these patients leads 
to higher levels of cardiac necrosis markers and 
lower left ventricular ejection fraction [9, 22]. It 
also leads to increased endothelial dysfunction, hy-
percoagulability and impaired fibrinolysis [23, 24]. 
ABG ≥ 8.9 mmol/L was found to be an independent 
prognostic factor of no-reflow phenomenon in the 
study by Iwakura et al. [21]. A similar correlation 
was reported by Ishihara et al. [25] for patients 
with ABG > 11.1 mmol/L.
In Gąsior et al. [11] study, higher incidence of 
CS complicating ACS was observed among patients 
with high BG levels (≥ 7.8 mmol/L). Also Worthley 
et al. [26] showed that CS development is a prog-
nostic implication of hyperglycemia in AMI. Zeller 
et al. [13] reported abnormal fasting glycemia as 
a predictor of CS.
Some studies have also confirmed the ef-
fect of hyperglycemia on increased mortality in 
patients with CS. In Pres et al. [14] research, 
evaluated BG level on admission (≥ 7.8 mmol/L), 
resulted in higher in-hospital and long-term mor-
tality in patients with STEMI complicated by CS. 
Also Valente et al. [15] in an univariate analysis 
showed that hyperglycemia (> 11.1. mmol/L) was 
an independent predictor of in-hospital mortality. 
However, multivariate analysis did not confirm 
this association. In Tada et al. [27] study, a group 
of 81 patients transported by ambulance with CS 
complicating ACS, demonstrated ABG level of 
9.2 mmol/L as a strongest prognostic indicator 
of death. It should be noted that in quoted study 
ACS was not the only cause of CS and the rate of 
in hospital death was only 12.3%.
In our study, there was no statistically sig-
nificant correlation between the level of glucose 
on admission to hospital and in-hospital mortality. 
Average ABG in patients who survived and in those 
who died did not differ significantly. Also compari-
son in groups depending on ABG level and calcula-
tions with use of receiver-operating characteristics 
curves showed no relationship between the level 
of glucose on admission and patients in-hospital 
death. Some other authors also did not confirm the 
prognostic value of ABG. Foo et al. [28] in a pro-
spective cohort study of 2,127 patients with ACS, 
demonstrated that admission serum glucose con-
centration was not independently associated with 
fatal outcome. In the univariate analysis, de Faria 
Modenesi et al. [29] reported that in 361 patients 
with ACS, the presence of stress hyperglycemia 
was associated with death but multivariate analysis 
did not confirm this finding. The report from the 
DIGAMI 2 trial [30] proved no relationship be-
tween 1-year risk of death, re-infarction or stroke 
and glycemic variability in DM patients with AMI 
who have been treated with insulin infusion during 
hospitalization.
Other studies report that hyperglycemia is 
a poor prognostic factor, but only in patients with-
out a prior history of DM. Vis et al. [31] inves-
tigated 208 consecutive non-DM patients with 
STEMI and CS on admission. ABG level was 
a strong independent predictor of 1-year mortal-
ity which was respectively 21%, 27% and 60% in 
groups selected depending on admission glycemia 
(≤ 7.8 mmol/L, 7.8–11.1 mmol/L and > 11.1 mmol/L; 
p < 0.001, respectively). It should be noted that 
all patients enrolled in this study had CS on admis-
sion. The latest study of Yang et al. [32] confirmed 
that in patients with STEMI complicated by CS, 
the ABG level was independently associated with 
increased risk of 30-day mortality and had an ad-
ditional predictive value for established risk score 
models in nondiabetic patients but not in diabetics. 
Unfortunately, the authors of this study could not 
identify the impact of BG lowering therapy on mor-
tality because data on BG levels during the course 
of hospitalization and therapeutic BG targets were 
not available in their registries.
Given such divergent results, prognostic value 
of hyperglycemia in patients with ACS still requires 
further studies. Specific group which includes CS 
patients needs extremely careful analysis. Despite 
few reports finding ABG as an independent risk 
factor of shock appearance [11, 13, 26] it is still 
not clear whether admission hyperglycemia is 
not just simply a manifestation of ongoing critical 
illness [6]. It is surely a characteristic feature of 
the already present CS. Therefore, the key issue 
is the time between collecting blood samples and 
the onset of the first CS symptoms. Further studies 
should reconsider whether admission hyperglyce-
mia or CS itself, as the most severe complication, 
determines death in ACS patients.
294 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 3
Limitations of the study
This is a single center registry. The primary 
limitation of this study was the small number of 
patients. The relatively low incidence of CS as 
a complication of ACS and the exclusion of pa-
tients transported from other hospitals, resulted in 
a significant reduction of the study group size. 
Other major limitation is the inability to evaluate 
the time window between collection of blood sam-
ples and occurrence of first CS symptoms.
Also because of the widely different clinical 
condition of patients before admission to the clinic, 
information about the time of the last meal was 
often impossible to obtain. Therapeutic interven-
tions and medications administered by ambulance 
personnel were significantly different in individual 
cases. In this study, we were unable to determine 
how these actions impacted the BG level on ad-
mission.
Conclusions
Hyperglycemia on admission is a clinical fea-
ture for patients with ACS who develop CS, how-
ever its prognostic value requires further studies.
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